vimarsana.com

Latest Breaking News On - சர்வதேச தரநிலை ஆன் விமர்சனம் ஈடுபாடுகள் - Page 1 : vimarsana.com

Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT  On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month period ending 30 June 2021,

Senior PLC (LSE:SNR) | RNS | Senior PLC - Interim Results

£50m for the full year ● ● Commenting on the results, David Squires, Group Chief Executive Officer of Senior plc, said: Our performance in the first half of 2021 has, once again, demonstrated the resilience of Senior.  While the global pandemic is not over, we are encouraged to see the clear signs of recovery in our end markets, which gives renewed confidence in our ability to create enhanced value for our investors over the medium term.  As we said in our 9 July 2021 Post-Close Trading Update, for 2021, despite the well-publicised headwinds associated with freight and commodity costs; semiconductor supply chain challenges for our land vehicle customers; as well as the divestment of our Senior Aerospace Connecticut business, we expect overall Group performance for 2021 to be slightly ahead of our previous expectations.  In relative terms, H1 2021 is likely to be slightly stronger than H2 2021 due to reduced defence sales in H2 2021, which, based on delivery profiles,

Royal Dutch Shell Plc (LSE:RDSA) | RNS | ROYAL DUTCH SHELL PLC 2ND QUARTER 2021 AND HALF YEAR UNAUDITED RESULTS

Royal Dutch Shell Plc (LSE:RDSA) | RNS | ROYAL DUTCH SHELL PLC 2ND QUARTER 2021 AND HALF YEAR UNAUDITED RESULTS
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.

PAO Severstal: Severstal reports Q2 2021 -3-

PAO Severstal: Severstal reports Q2 2021 -3-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.